Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Healios K.K. (4593.T)
JPY280.00
+19.00 (+7.28%)
JP JPX Healthcare Biotechnology
Address
Yurakucho Denki Building 100-0006
Tokyo, JP
Tokyo, JP
CEO
Tadahisa S. Kagimoto
Website
healios.co.jp
IPO
2015-06-16
ISIN JP3835100003
Also trades on
Other OTC · HLOSF (USD)
Tokyo Stock Exchange · 4593.T (JPY)
Description
Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets including Japan, Europe, and the United States. Its robust pipeline features several cellular and tissue-based products, such as HLCR011 and HLCR012, which are induced pluripotent stem cell (iPSC)-derived regenerative medicines aimed at treating age-related macular degeneration. Another iPSC-based therapy, HLCL041, is being developed for metabolic liver disease. Furthermore, Healios is progressing HLCM051, a regenerative treatment designed for ischemic stroke and acute respiratory distress syndrome, alongside HLCN061 for solid tumor indications. The company also maintains a joint research partnership with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies to combat mesothelioma. Healios K.K. adopted its current name in September 2013, having previously operated under the name Retina Institute Japan, K.K.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY280.00
+19.00 (+7.28%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.40
Float Shares
59.89M
Free Float %
55.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.19% | -2.31% | -8.38% | -8.13% | -24.83% | +20.64% | -6.35% | +12.62% | -77.74% | -78.98% | -79.92% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
280.00
Ratings Trend (MoM)
83% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.22
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-81.4% Q1'26: -78.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+57.0% ★ Q1'26: -3.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-3,522.1% Q1'26: -16,325.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-3,272.1% Q1'26: -14,300.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-185.8% Q1'26: +649.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+21.7% Q1'26: +31.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.84× Q1'26: -0.60× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 5 Rev. Ana. 5 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
98.17M
est: 98.00M (+0.2%)
|
77.64M
est: 109.00M (-28.8%)
|
27.67M
est: 27.00M (+2.5%)
|
89.00M
est: 42.00M (+111.9%)
|
27.00M
est: 13.50M (+100.0%)
|
41.00M
est: 96.00M (-57.3%)
|
90.00M
est: 22.00M (+309.1%)
|
121.00M
est: 521.00M (-76.8%)
|
560.00M
est: 300.00M (+86.7%)
|
104.00M
est: 745.67M (-86.1%)
|
542.82M
78.34M – 1.76B
-27.2% YoY
|
9.75B
249.07M – 34.62B
+1,696.8% YoY
|
20.33B
20.02B – 20.64B
+108.5% YoY
|
15.24B
2.20B – 49.37B
-25.0% YoY
|
32.95B
4.76B – 106.72B
+116.2% YoY
|
| EBITDA |
-932.35M
est: -98.00M (-851.4%)
|
-3.23B
est: -109.00M (-2,864.6%)
|
-1.64B
est: -27.00M (-5,990.3%)
|
-4.17B
est: -42.00M (-9,823.8%)
|
-3.97B
est: -13.50M (-29,292.6%)
|
-3.61B
est: -96.00M (-3,663.5%)
|
-4.52B
est: -22.00M (-20,431.8%)
|
-3.16B
est: -521.00M (-506.0%)
|
-2.55B
est: -300.00M (-748.3%)
|
-3.13B
est: -745.67M (-319.5%)
|
-542.82M
-1.76B – -78.34M
+27.2% YoY
|
-9.75B
-34.62B – -249.07M
-1,696.8% YoY
|
-20.33B
-20.64B – -20.02B
-108.5% YoY
|
-15.24B
-49.37B – -2.20B
+25.0% YoY
|
-32.95B
-106.72B – -4.76B
-116.2% YoY
|
| EBIT |
-1.06B
est: -98.00M (-982.1%)
|
-3.40B
est: -109.00M (-3,019.9%)
|
-1.75B
est: -27.00M (-6,363.0%)
|
-4.31B
est: -42.00M (-10,157.1%)
|
-4.20B
est: -13.50M (-30,981.5%)
|
-3.88B
est: -96.00M (-3,936.5%)
|
-4.90B
est: -22.00M (-22,186.4%)
|
-3.38B
est: -521.00M (-548.9%)
|
-2.84B
est: -300.00M (-847.3%)
|
-3.40B
est: -745.67M (-356.4%)
|
-542.82M
-1.76B – -78.34M
+27.2% YoY
|
-9.75B
-34.62B – -249.07M
-1,696.8% YoY
|
-20.33B
-20.64B – -20.02B
-108.5% YoY
|
-15.24B
-49.37B – -2.20B
+25.0% YoY
|
-32.95B
-106.72B – -4.76B
-116.2% YoY
|
| Net Income |
-958.10M
est: -2.26B (+57.7%)
|
-3.43B
est: -7.60B (+54.8%)
|
-1.78B
est: -3.34B (+46.8%)
|
-4.41B
est: -6.31B (+30.1%)
|
-5.51B
est: -8.72B (+36.8%)
|
-4.91B
est: -7.75B (+36.6%)
|
-5.17B
est: -5.94B (+12.9%)
|
-3.82B
est: -5.39B (+29.1%)
|
-4.24B
est: -5.99B (+29.3%)
|
-2.22B
est: -2.22B (+0.0%)
|
-4.45B
-16.23B – 466.51M
-100.6% YoY
|
-3.81B
-6.59B – -162.61M
+14.3% YoY
|
-126.26M
-4.11B – 15.25B
+96.7% YoY
|
-212.20M
-829.75M – 23.85M
-68.1% YoY
|
7.97B
-895.85M – 31.17B
+3,856.8% YoY
|
| SGA |
356.62M
est: 2.28B (-84.3%)
|
447.03M
est: 2.53B (-82.4%)
|
541.88M
est: 627.63M (-13.7%)
|
1.01B
est: 976.31M (+3.9%)
|
1.24B
est: 313.81M (+294.8%)
|
1.72B
est: 2.23B (-22.8%)
|
1.45B
est: 511.40M (+183.3%)
|
1.18B
est: 8.32B (-85.8%)
|
1.37B
est: 4.79B (-71.3%)
|
990.00M
est: 11.91B (-91.7%)
|
8.67B
1.25B – 28.08B
-27.2% YoY
|
155.78B
3.98B – 552.93B
+1,696.8% YoY
|
324.76B
319.79B – 329.73B
+108.5% YoY
|
243.45B
35.14B – 788.46B
-25.0% YoY
|
526.29B
75.96B – 1.70T
+116.2% YoY
|
| EPS |
-25.60
est: -25.60 (+0.0%)
|
-84.33
est: -85.90 (+1.8%)
|
-39.73
est: -37.77 (-5.2%)
|
-87.94
est: -71.31 (-23.3%)
|
-107.21
est: -98.61 (-8.7%)
|
-93.40
est: -87.57 (-6.7%)
|
-90.69
est: -67.09 (-35.2%)
|
-56.22
est: -67.71 (+17.0%)
|
-47.87
est: -39.90 (-20.0%)
|
-20.59
est: -35.01 (+41.2%)
|
-38.56
-150.79 – 4.33
-10.1% YoY
|
-28.84
-61.19 – -1.51
+25.2% YoY
|
8.83
-38.15 – 141.69
+130.6% YoY
|
-1.97
-7.71 – 0.22
-122.3% YoY
|
74.05
-8.32 – 289.56
+3,856.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-6.13B
OE per share TTM
-58.12
Owner's Yield
-17.40%
Maintenance CapEx ratio
2.60%
Maint CapEx / Avg PPE
613.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis International Small Cap Equity ETF AVDS | 0.00% | 324.29 | 0.30% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-523.5K
Shares Outstanding
107.66M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hironobu Kimura | Executive Officer & Head of Kobe Research Institute | — | — |
| Richard Kincaid | Executive Officer, Chief Financial Officer & Director | — | male |
| Tadahisa S. Kagimoto | Chairman, Representative Executive Officer, President & CEO | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4593.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
